The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.
Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.
Male or female age 60-85 years.
Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.
A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.
Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.
Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.
History of Epileptic Seizures or Epilepsy.
Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.
Advanced Technology & Communications
Lead sponsor
Chungnam National University Hospital
Collaborator
Korea University Anam Hospital
Collaborator
Dong-A University Hospital
Collaborator
Chonnam National University Hospital
Collaborator
Chonbuk National University Hospital
Collaborator
Chung-Ang University Gwangmyeong Hospital
Collaborator
Yeungnam University Hospital
Collaborator
Inje University Ilsan Paik Hospital
Collaborator
National Health Insurance Service Ilsan Hospital
Collaborator
Konkuk University Medical Center
Collaborator